Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Low Anterior Resection Syndrome 1Gastroparesis 1Esophageal Neoplasms 1Esophageal Motility Disorders 1Esophageal Diseases 1Esophageal Achalasia 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Botulinum Toxins, Type A × Gastrointestinal × Clear all
NCT01589471 2018-02-12

The Value of Botox-A for Management of Low Anterior Resection Syndrome

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 2 Completed
23 enrolled
Gastrointestinal

Low Anterior Resection Syndrome, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡